Interview with John Norman, Country Manager, Nycomed South Africa
Mr Norman, could you tell us a few words on the transformation process that the company is currently going through? Takeda acquired Nycomed in October 2011, because it was an…
Address: 1 Libertas Road
Cnr Main Road and Sloane Street
Bryanston, Johannesburg
2191,South Africa
Tel: +27 (0) 11 514 3000
Web: http://www.takeda.co.za/za/
The South African arm of Nycomed has its origins in 1996 when two German companies, Byk Gulden and Madaus AG entered into a joint venture in South Africa and Byk Madaus was created. All products were managed in one combined portfolio and came from either Byk Gulden, Madaus or were in-licenced from other companies. Packaging, warehousing and distribution operations were carried out at a warehouse facility in Midrand.
In 2001, the company outsourced its distribution to PHD.
In 2002, Altana Pharma was launched when Altana bought out the Byk portion of the Byk Madaus joint venture.
In 2003 a further name change took place and the company became the South African joint venture known as Altana Madaus. It was during this period that a separate OTC and Rx division were launched, the Midrand facility was sold and the company moved from Midrand to Woodmead.
In 2007 Nycomed GmbH acquired Altana Pharma and Rottapharm acquired Madaus GmbH. A further name change took place and the local company became known as Nycomed Madaus.
In 2008, Nycomed GmbH acquired the Madaus 50% share of the joint venture and the South African business now falls under the sole control of the Nycomed group of companies.
The South African product range encompasses both licensed and in-licensed OTC (Over the Counter) and Rx (prescription) products. These products are marketed and distributed nationally.
The Rx* product range covers the following treatment areas:
Respiratory
Anti-Epileptic
Urinary Tract
Iron
Liver
Gastro Intestinal
Pain and Inflamation
* In terms of South African legislation, scheduled products may not be marketed to the public and the brands have therefore not been mentioned on this website
The OTC product range encompasses the following treatment areas and products:
Laxatives – Agiolax® and Agiobulk®
Tranquiliser – Biral®
Pain and Inflammation – Empaped®, Reparil®, Dona®
Vitamin and Mineral – Emvit®, Emvit®.M, Emvit® Cal-D3, Magnesit®
Iron – Ferrimed®
Sun care – Piz Buin®
Mr Norman, could you tell us a few words on the transformation process that the company is currently going through? Takeda acquired Nycomed in October 2011, because it was an…
Building on the recent controversy over Tanzania’s handling of a suspected Marburg virus outbreak, Medicines for Africa’s Lenias Hwenda explores how African nations often face disproportionate consequences for outbreak transparency—penalties…
John M. Mwangi of Bayer Pharmaceuticals, writing in the December 2024 edition of DIA’s Global Forum magazine, examines why longstanding calls to implant more of the pharmaceutical manufacturing chain into…
The IFPMA’s Sarah Adam, writing in the July 2024 edition of DIA’s Global Forum magazine, looks back on an insightful discussion on the progress towards an African Medicines Agency at…
Several major scientific breakthroughs in HIV prevention and treatment in the past 40 years have successfully transformed HIV from a near-certain ‘death sentence’ to a manageable chronic disease where many…
In 2024, people living with HIV have more, and more varied, access to HIV prevention and treatment options than ever before. Thanks to global activism efforts forcing pharma to step…
A leading voice in the global fight against HIV, Professor Linda-Gail Bekker works across both scientific research and activism. As CEO and founder of the Desmond Tutu Health Foundation, Prof…
Medicines for Africa’s Lenias Hwenda reflects on Moderna’s recent decision not to go ahead with plans for a vaccine manufacturing facility in Kenya, and why local production remains crucial to…
Medicines for Africa’s Lenias Hwenda argues that the success of the much-talked-about African Medicines Agency hinges on a critical mass of African national regulators achieving WHO Level 3 maturity status.…
Writing in the February 2024 edition of the DIA Global Forum magazine, Verena Pfaffinger and Ilona Baraniak-Lang of PharmaLex examine how the drug shortages seen in the global south during…
Tremendous strides have been made in both treatment and prevention of AIDS and it is no longer among the 10 leading causes of death globally, however an estimated 39 million…
Dr Benji Pretorius, the founder of Erada Technology Alliance and a malaria survivor himself, shares his insights into why the development of a truly effective malaria vaccine will only succeed…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Nevena Miletic of Roche and the IFPMA’s Africa Regulatory Network and Ian Hudson from the Bill and Melinda Gates…
See our Cookie Privacy Policy Here
